Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.

March 06, 2026

Vol.52 No.09

By Jacquelyn Cobb and Sara Willa Ernst

Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.

March 06, 2026

Vol.52 No.09

By Jacquelyn Cobb and Sara Willa Ernst

Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

March 06, 2026

Vol.52 No.09

By Jacquelyn Cobb and Sara Willa Ernst

Cancer Policy

House member introduces bill to increase funding for MCD testing of firefighters

Rep. Josh Gottheimer (D-NJ) introduced the FIRE Cancer Act on Feb. 27. The piece of legislation seeks to increase grant dollars available to local fire departments, specifically earmarked for cancer prevention, “including providing multi-cancer early detection testing or other forms of preventative tests.”

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

High-level results from the randomized, controlled NHS-Galleri trial, which is evaluating GRAIL’s multi-cancer screening test, Galleri, over three years in 142,000 participants aged 50 to 77, reveals that the trial did not meet its primary endpoint of shifting cancer diagnosis from advanced stages (3 and 4) to earlier stage (1 and 2).

February 27, 2026

Vol.52 No.08

By Sara Willa Ernst

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risks
Respirators (restricted by federal regulation) may or may not be the answer

The call to Fire Captain Brian Buchanan and his crew came at midnight. Northern California firefighters were urgently needed to help fight the wildfires that were devouring big swaths of Los Angeles.

February 20, 2026

Vol.52 No.07

By Sara Willa Ernst

Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

YOU MAY BE INTERESTED IN

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

House member introduces bill to increase funding for MCD testing of firefighters

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risks
Respirators (restricted by federal regulation) may or may not be the answer

Renew today!

Subscriber content

Never miss an issue!

Login

Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

YOU MAY BE INTERESTED IN

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

House member introduces bill to increase funding for MCD testing of firefighters

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risksRespirators (restricted by federal regulation) may or may not be the answer

Never miss an issue!

Login

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risks
Respirators (restricted by federal regulation) may or may not be the answer